In HER2-positive early breast cancer, anti-HER2 therapy together with neoadjuvant chemotherapy has become the standard of care as achievement of pathological complete response is correlated with improved progression-free survival and disease-free survival [10]. The gene discussed is ERBB2; the disease is breast carcinoma.